Jove
Visualize
Contact Us

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Local Anesthetics: Clinical Application as Epidural Anesthesia01:29

Local Anesthetics: Clinical Application as Epidural Anesthesia

Epidural anesthetics are administered in the fat-filled epidural space, the outermost part of the spinal canal. This technique is commonly employed for pain management and anesthesia during lower abdomen and pelvis surgeries or labor and delivery.
Since epidural anesthetics can be infused through an epidural catheter, all types of drugs, including short-acting ones, can be administered. Chloroprocaine and lidocaine are examples of short and long-duration anesthetics, respectively. Bupivacaine...
Acute Inflammation III: Local and Systemic Effects01:25

Acute Inflammation III: Local and Systemic Effects

Acute inflammation produces a coordinated set of local and systemic changes that limit injury, eliminate pathogens, and initiate repair. These responses arise within minutes of infection, trauma, or chemical insult and are driven by vascular alterations and leukocyte-derived mediators. When the stimulus resolves, the reaction typically abates within days.Local EffectsAt the site of injury, arteriolar vasodilation increases blood flow, resulting in redness and warmth. Simultaneously, increased...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Involvement of cystathionine β-synthase in ATP-induced hydrogen sulfide production in cochlear outer hair cells.

Journal of otology·2026
Same author

Involvement of Ca<sub>v</sub>3.2 T-Type Ca<sup>2+</sup> Channels and the Role of Endogenous Estrogen in Pruritus: Evidence from a Fundamental Study and Cross-Sectional Analysis of Pharmacy Claims Data.

Biological & pharmaceutical bulletin·2026
Same author

[Preface].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same author

[Chemotherapy-induced peripheral neuropathy and sex hormones].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same author

[Effectiveness of Angiotensin System Inhibitors Against Painful Peripheral Neuropathy in Type 2 Diabetic Old Patients: Validation by Analysis of Pharmacy Claims Data].

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan·2025
Same author

Identification of potentially inappropriate medications characteristic of older individuals with diabetes: a study using pharmacy claims data.

Journal of pharmaceutical health care and sciences·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 30, 2026

Collecting And Measuring Wound Exudate Biochemical Mediators In Surgical Wounds
04:58

Collecting And Measuring Wound Exudate Biochemical Mediators In Surgical Wounds

Published on: October 20, 2012

Prostaglandin E2 and pain--an update.

Atsufumi Kawabata1

  • 1Division of Pharmacology and Pathophysiology, School of Pharmacy, Kinki University, Higashi-Osaka 577–8502, Japan. kawabata@phar.kindai.ac.jp

Biological & Pharmaceutical Bulletin
|August 2, 2011
PubMed
Summary

Prostaglandin E(2) (PGE(2)) drives inflammatory pain. Targeting its pathways offers new therapeutic strategies for pain relief with potentially fewer side effects than traditional NSAIDs.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Neuroscience

Background:

  • Prostaglandin E(2) (PGE(2)) is a key lipid mediator in inflammatory pain, produced via cyclooxygenase (COX) enzymes.
  • Nonsteroidal anti-inflammatory drugs (NSAIDs) reduce PGE(2) but cause significant toxicities.
  • PGE(2) also contributes to neuropathic pain, visceral pain, and migraine.

Purpose of the Study:

  • To explore novel therapeutic strategies for intractable pain by targeting Prostaglandin E(2) (PGE(2)) signaling pathways.
  • To evaluate the potential of selective EP(1) and EP(4) receptor antagonists and microsomal PGE synthase-1 inhibitors as safer analgesics.

Main Methods:

  • The study reviews the role of PGE(2) in pain signaling, including its downstream effects.
  • It examines the mechanisms by which Protein Kinase C (PKC) and Protein Kinase A (PKA) mediate hyperalgesia via ion channels and receptors.

More Related Videos

An Experimental Paradigm for the Prediction of Post-Operative Pain (PPOP)
14:56

An Experimental Paradigm for the Prediction of Post-Operative Pain (PPOP)

Published on: January 27, 2010

Related Experiment Videos

Last Updated: May 30, 2026

Collecting And Measuring Wound Exudate Biochemical Mediators In Surgical Wounds
04:58

Collecting And Measuring Wound Exudate Biochemical Mediators In Surgical Wounds

Published on: October 20, 2012

An Experimental Paradigm for the Prediction of Post-Operative Pain (PPOP)
14:56

An Experimental Paradigm for the Prediction of Post-Operative Pain (PPOP)

Published on: January 27, 2010

  • Focuses on the therapeutic potential of inhibiting upstream and downstream components of the PGE(2) pathway.
  • Main Results:

    • PGE(2) activates nociceptors through EP(1) and EP(4) receptors, leading to hyperalgesia via PKC and PKA signaling.
    • Downstream targets include TRPV1 channels, P2X3 receptors, and voltage-gated ion channels.
    • Selective inhibition of PGE(2) synthesis or receptor antagonism shows promise for pain management.

    Conclusions:

    • Prostaglandin E(2) (PGE(2)) plays a critical role in various pain conditions.
    • Targeting specific PGE(2) receptors (EP(1), EP(4)) or synthesis pathways offers potential for developing analgesics with improved safety profiles.
    • Intervention in PGE(2) upstream and downstream signaling represents a promising avenue for treating difficult-to-manage pain.